MA30959B1 - Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp - Google Patents

Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp

Info

Publication number
MA30959B1
MA30959B1 MA31938A MA31938A MA30959B1 MA 30959 B1 MA30959 B1 MA 30959B1 MA 31938 A MA31938 A MA 31938A MA 31938 A MA31938 A MA 31938A MA 30959 B1 MA30959 B1 MA 30959B1
Authority
MA
Morocco
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
pharmaceutically acceptable
ksp
Prior art date
Application number
MA31938A
Other languages
English (en)
Inventor
Yi Xia
Kris G Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Paul A Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30959B1 publication Critical patent/MA30959B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE PYRAZOLE ET DE TRIAZOLE SUBSTITUÉS REPRÉSENTÉS PAR LA FORMULE (I), ET DES SELS, DES ESTERS OU DES PROMÉDICAMENTS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI, DES COMPOSITIONS DE CES DÉRIVÉS CONTENANT DES EXCIPIENTS PHARMACEUTIQUEMENT ACCEPTABLES AINSI QUE DES UTILISATIONS DE CELLES-CI.
MA31938A 2006-11-13 2009-06-01 Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp MA30959B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
MA30959B1 true MA30959B1 (fr) 2009-12-01

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31938A MA30959B1 (fr) 2006-11-13 2009-06-01 Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp

Country Status (32)

Country Link
US (2) US7902240B2 (fr)
EP (1) EP2091926B1 (fr)
JP (1) JP5264755B2 (fr)
KR (1) KR20090081020A (fr)
CN (1) CN101558049B (fr)
AR (1) AR063805A1 (fr)
AU (1) AU2007323998B2 (fr)
BR (1) BRPI0719002A2 (fr)
CA (1) CA2668661A1 (fr)
CL (1) CL2007003272A1 (fr)
CO (1) CO6382171A2 (fr)
CR (1) CR10787A (fr)
DO (1) DOP2009000106A (fr)
EA (1) EA017748B1 (fr)
EC (1) ECSP099326A (fr)
ES (1) ES2557478T3 (fr)
GE (1) GEP20125389B (fr)
GT (1) GT200900122A (fr)
HN (1) HN2009000968A (fr)
IL (1) IL198471A0 (fr)
MA (1) MA30959B1 (fr)
MX (1) MX2009005071A (fr)
NI (1) NI200900084A (fr)
NO (1) NO20092226L (fr)
NZ (1) NZ576640A (fr)
PE (1) PE20081169A1 (fr)
SM (1) SMP200900045B (fr)
TN (1) TN2009000178A1 (fr)
TW (1) TW200831480A (fr)
UA (1) UA97256C2 (fr)
WO (1) WO2008063912A1 (fr)
ZA (1) ZA200902940B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902240B2 (en) * 2006-11-13 2011-03-08 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
WO2008086122A2 (fr) * 2007-01-05 2008-07-17 Novartis Ag Dérivés cyclisés en tant qu'inhibiteurs d'eg-5
WO2011128388A2 (fr) * 2010-04-15 2011-10-20 Novartis Ag Composés d'oxazole et de thiazole comme inhibiteurs de ksp
AU2011239977B2 (en) * 2010-04-15 2014-11-27 Novartis Ag Triazole compounds as KSP inhibitors
WO2014089140A1 (fr) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Procédé de préparation d'inhibiteurs de transcriptase inverse
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
WO2014151030A1 (fr) * 2013-03-15 2014-09-25 Novartis Ag Inhibiteurs de la prolifération cellulaire et leurs conjugués
EP3077376B1 (fr) 2013-12-04 2019-10-16 Merck Sharp & Dohme Corp. Procédé de préparation d'inhibiteurs de transcriptase inverse
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
US20190161499A1 (en) * 2015-12-11 2019-05-30 Syngenta Participations Ag Pesticidally active 1,2,4-triazole derivatives
US11091447B2 (en) 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
KR20020062930A (ko) 1999-10-27 2002-07-31 싸이토키네틱스, 인코포레이티드 퀴나졸리논을 사용하는 방법 및 조성물
CA2425185A1 (fr) 2000-10-06 2002-04-11 Stephane De Lombaert Derives de benzimidazole et d'indole en tant que modulateurs des recepteurs de la corticoliberine
EP1360180A1 (fr) 2001-01-19 2003-11-12 Cytokinetics, Inc. Inhibiteurs de la kinesine a base de phenothiazine
EP1351671A1 (fr) 2001-01-19 2003-10-15 Cytokinetics, Inc. Inhibiteurs triphenylmethane de la kinesine
CA2465491A1 (fr) 2001-11-07 2003-05-15 Merck & Co., Inc. Inhibiteurs de la kinesine mitotique
CA2466033A1 (fr) 2001-11-08 2003-05-15 The University Of Chicago Methode de traitement de troubles lies a un taux de cholesterol eleve
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7262186B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
ATE447577T1 (de) 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
AU2002364128B2 (en) 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
JP2005516004A (ja) * 2001-12-07 2005-06-02 ヴァージニア コモンウェルス ユニバーシティ 新形成の治療
EP1465888A2 (fr) 2002-01-10 2004-10-13 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
JP4399269B2 (ja) 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
WO2003097053A1 (fr) 2002-05-09 2003-11-27 Cytokinetics, Inc. Composes, compositions et procedes
JP2006508030A (ja) 2002-05-09 2006-03-09 サイトキネティクス・インコーポレーテッド ピリミジノン化合物、組成物および方法
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
WO2003103575A2 (fr) 2002-05-23 2003-12-18 Cytokinetics, Inc. Composes, compositions et procedes
CA2483627A1 (fr) 2002-05-23 2003-12-04 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
MXPA04012642A (es) 2002-06-14 2005-03-23 Merck & Co Inc Inhibidores de la cinesina mitotica.
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン結合部位
EP1539727B1 (fr) 2002-07-17 2009-02-18 Cytokinetics, Inc. Composes, compositions et methodes pour le traitement des maladies proliferatives cellulaires
EP1537089A4 (fr) 2002-07-23 2008-04-16 Cytokinetics Inc Composes, compositions et procedes
JP2005536553A (ja) 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
WO2004103282A2 (fr) 2003-05-15 2004-12-02 Cytokinetics, Inc. Composes, compositions et procedes
CA2561904A1 (fr) 2004-04-06 2005-10-27 Chiron Corporation Inhibiteurs de la kinesine mitotique
DK1753723T3 (da) * 2004-05-21 2008-10-20 Novartis Vaccines & Diagnostic Substituerede quinolinderivater som mitotiske kinesininhibitorer
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
WO2006049835A2 (fr) 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics Inc. Derives d'indole et de benzimidazole
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
MY147188A (en) * 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
US7902240B2 (en) * 2006-11-13 2011-03-08 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors

Also Published As

Publication number Publication date
IL198471A0 (en) 2010-02-17
HN2009000968A (es) 2011-10-25
TW200831480A (en) 2008-08-01
PE20081169A1 (es) 2008-09-24
CL2007003272A1 (es) 2008-03-24
US20080200462A1 (en) 2008-08-21
AR063805A1 (es) 2009-02-18
KR20090081020A (ko) 2009-07-27
CR10787A (es) 2009-07-02
TN2009000178A1 (en) 2010-10-18
CN101558049A (zh) 2009-10-14
GEP20125389B (en) 2012-01-25
CN101558049B (zh) 2012-08-15
EA017748B1 (ru) 2013-02-28
WO2008063912A1 (fr) 2008-05-29
ES2557478T3 (es) 2016-01-26
US20100034813A1 (en) 2010-02-11
ECSP099326A (es) 2009-06-30
GT200900122A (es) 2011-09-14
AU2007323998B2 (en) 2011-09-22
JP2010509365A (ja) 2010-03-25
US8129358B2 (en) 2012-03-06
EP2091926B1 (fr) 2015-10-21
US7902240B2 (en) 2011-03-08
EP2091926A1 (fr) 2009-08-26
SMAP200900045A (it) 2009-07-14
UA97256C2 (ru) 2012-01-25
ZA200902940B (en) 2010-05-26
NO20092226L (no) 2009-08-12
CA2668661A1 (fr) 2008-05-29
MX2009005071A (es) 2009-05-25
NI200900084A (es) 2010-01-29
AU2007323998A1 (en) 2008-05-29
NZ576640A (en) 2011-10-28
SMP200900045B (it) 2010-03-01
EA200900631A1 (ru) 2009-12-30
JP5264755B2 (ja) 2013-08-14
DOP2009000106A (es) 2009-05-31
CO6382171A2 (es) 2012-02-15
BRPI0719002A2 (pt) 2013-12-17

Similar Documents

Publication Publication Date Title
MA30959B1 (fr) Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
MA30781B1 (fr) Inhibiteur de kinase
MA29909B1 (fr) Derives de pyridazine
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
TW200612958A (en) Substituted imidazole derivatives
TN2009000544A1 (fr) Derives de benzimidazole
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
MA31580B1 (fr) Derives de bicyclolactames substitués
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
TW200833675A (en) Nicotinamide derivatives
TN2009000450A1 (fr) Derives de pyridine
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MA32151B1 (fr) Derives de 2-aza-bicyclo[2.2.1]heptane
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA30819B1 (fr) Nouvelle diphenylazetidinone substituee par l'acide piperazin-1-sulfonique et presentant des proprietes pharmacologiques ameliorees
WO2007109578A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques